Phase 2 Trial Evaluates Fenebrutinib Dosing in Children With Relapsing MS

21 Oct 2026 0 comments

The phase 2 FENerations1 study is evaluating fenebrutinib dosing in 8 to 12 children and adolescents with relapsing MS with pediatric pharmacokinetic and safety findings not yet reported.

Source: NeurologyLive Published 21 Oct 2026 Imported 21 Oct 2026 Relevancy: Not reviewed

Read the article

Comments

No comments yet.

Unrestricted

All comments are reviewed before being published. Most comments are approved unless they are clearly inappropriate or unsafe.

Comments

Leave a comment